Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis US has announced that Aplenzin extended-release tablets, an effective bupropion therapy for the treatment of major depressive disorder, is now available by prescription in the US for adults ages 18 and older.
Subscribe to our email newsletter
Aplenzin differs from other generic and branded bupropion antidepressants because it provides a unique HBr salt extended-release formulation, offering prescribers and their patients the benefit of convenience with simple one tablet, once-daily dosing at all doses, the company said.
Sanofi-Aventis US, which licensed Aplenzin from Biovail in December 2008, markets the product in the US and Puerto Rico.
Brent Ragans, vice president and head of the general therapeutics business unit at Sanofi-Aventis, said: “With major depressive disorder affecting about 14 million Americans, we are excited to offer patients an effective treatment option that hopefully addresses existing unmet needs.”